Welcome to our dedicated page for Mobix Labs SEC filings (Ticker: MOBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Mobix Labs鈥� progress means wading through pages packed with RF engineering talk, defense export rules, and supply-chain diagrams. If finding R&D spend or a design-win update in the latest 10-K feels daunting, you鈥檙e not alone.
Stock Titan solves that problem. Our AI reads every Mobix Labs annual report 10-K simplified, Mobix Labs quarterly earnings report 10-Q filing, and Mobix Labs 8-K material events explained the moment they hit EDGAR. It extracts what professionals actually need鈥攃hip sales by end-market, defense-contract exposure, pending patents鈥攖hen writes a plain-English brief you can absorb in minutes. Want to follow Mobix Labs insider trading Form 4 transactions? AG真人官方-time alerts show executive stock moves before markets react, so you can monitor Mobix Labs executive stock transactions Form 4 without refreshing a spreadsheet.
Here鈥檚 what you鈥檒l uncover on this page:
- 10-K & 10-Q鈥擜I breakdowns of revenue by automotive, medical, and aerospace customers, plus year-over-year R&D trends.
- 8-K鈥擨nstant summaries whenever design-wins, supply-chain disruptions or leadership changes surface.
- Form 4鈥擬obix Labs Form 4 insider transactions real-time, helping you track buying before new product announcements.
- DEF 14A proxy statement executive compensation analysis outlining option grants tied to RF innovation milestones.
Whether you鈥檙e comparing quarter-over-quarter gross margin shifts or simply understanding Mobix Labs SEC documents with AI, every filing is here, already explained, and continuously updated. Save hours, gain clarity, and make informed decisions with data that matters.
Disc Medicine, Inc. (IRON) 鈥� Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Disc Medicine, Inc. (IRON) 鈥� Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Disc Medicine, Inc. (IRON) 鈥� Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Disc Medicine, Inc. (IRON) 鈥� Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Disc Medicine, Inc. (IRON) 鈥� Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Disc Medicine, Inc. (IRON) 鈥� Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Disc Medicine, Inc. (IRON) 鈥� Form 4 insider transaction filed 07/11/2025
Chief Executive Officer and Director John D. Quisel reported one option exercise and two open-market sales executed on 07/09/2025 under a Rule 10b5-1 trading plan adopted 02/13/2025.
- Option exercise (Code M): 34,800 shares exercised at $9.86 per share, sourced from a September 1 2021 option award that vests in 48 equal monthly installments.
- Sales (Code S): Entire 34,800 exercised shares were sold the same day in two tranches: 31,207 shares at a weighted-average $55.2312 (range $55.00-$55.99) and 3,593 shares at a weighted-average $56.1995 (range $56.00-$56.33).
- Net share position: Beneficial ownership briefly rose to 196,628 shares post-exercise, but fell back to 161,828 shares after the sales, resulting in no net change versus the pre-transaction stake.
The filing indicates routine liquidity management by the CEO; no company cash flows are affected. Because transactions were pre-planned and the overall ownership level is unchanged, market impact is likely limited.
Mobix Labs, Inc. (Nasdaq: MOBX) filed an 8-K to disclose that on 26 June 2025 it issued a press release (Exhibit 99.1) announcing an unsolicited, non-binding stock-for-stock proposal to acquire Peraso Technologies Inc. (Nasdaq: PRSO).
Key disclosed terms:
- Mobix would issue newly-created MOBX Class A shares for every Peraso share.
- The exchange ratio is structured to deliver a 20 % premium to Peraso鈥檚 30-day volume-weighted average closing price through 10 June 2025.
The filing is furnished under Item 7.01 (Regulation FD); therefore, it is not deemed filed for liability purposes under Section 18 of the Exchange Act. The document contains typical forward-looking-statement language that highlights execution, regulatory and market risks. No additional financial statements or pro-forma information are included.
Because the proposal is unsolicited and non-binding, completion of any transaction remains uncertain and depends on Peraso鈥檚 response, due-diligence outcomes, regulatory clearance and potential shareholder approval requirements.
FAQ
What is the current stock price of Mobix Labs (MOBX)?
What is the market cap of Mobix Labs (MOBX)?
What core products does Mobix Labs Inc offer?
In which industries does Mobix Labs Inc operate?
How does Mobix Labs Inc generate revenue?
What differentiates Mobix Labs Inc from its competitors?
How does the company ensure product reliability?
What market needs does Mobix Labs Inc address?
Does Mobix Labs Inc focus on innovation?
How does Mobix Labs Inc contribute to high-demand industries?
